Health technology company Century Health announced on Thursday that it has partnered with Tessel Biosciences, a US-based biotechnology company that combines human organoids and machine learning to model chronic disease.

Under the collaboration, Tessel will leverage Century Health's COPD real-world dataset to characterise key patient subgroups that can benefit from its programmes in development for muco-obstructive lung disease. The partnership aligns with Tessel's stated mission to raise the predictive validity of drug development by including human cells, human data, and functional phenotypes into the discovery process.

Vish Srivastava, Century Health co-founder & CEO, said: "This partnership illustrates how AI-curated real-world data can meaningfully inform early drug development. The data we need for much of this advancement already exists in electronic records. Century Health's data abstraction helps Tessel better and more quickly understand patient subgroups that may be most relevant for targeted therapies."